##  [Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)](/us-en/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa-0 "Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)") 

  Jan 04, 2018